132549A UK - India Collaboration to Drive Innovation in Cervial Cancer ScreeningClosedFeasibility StudiesInnovate UKCervical cancer is the leading cause of cancer death in Indian women between the ages of 30 and 69. Only around 3.1% of women undergo screening tests in India versus 77.5% in the UK, a discrepancy meaning that the age standardised mortality rate from this disease is almost 7 times higher in India. This project aims to conduct market research and further establish a relationship between the UK lead organisation Sense Biodetection Limited and Indian diagnostics company Bhat Bio-Tech alongside clinical experts at SDM Medical College Hospital. Our long-term aim is to collaboratively develop and market a novel cervical cancer screening product in the form of a low cost, single-use molecular test for detection of infection by High Risk Human Papilloma Virus (hrHPV) which is directly linked with 99.7% of cervical cancer cases. In contrast to existing approaches, our test would eliminate the need for centralised testing facilities and infrastructure and so overcome barriers to adoption in the Indian market. Through initially focussing on the Indian market, we will develop a low-cost solution that also has wider potential to alleviate the costly burden of cervical screening within the NHS.